34 - 29 Psychopharmacological Treatment
01 - 29.1 General Principles of Psychopharmacology
29.1 General Principles of Psychopharmacology Psychopharmacological Treatment 29.1 General Princi...
02 - 29.2 Medication Induced Movement Disorders
29.2 Medication-Induced Movement Disorders Silva S, Swanson JM, van Zwieten-Boot B, Vitiello B, W...
03 - 29.3 a2 Adrenergic Receptor Agonists, a1 Adre
29.3 a2-Adrenergic Receptor Agonists, a1-Adrenergic Receptor Antagonists: Clonidine, Guanfacine, ...
04 - 29.4 b Adrenergic Receptor Antagonists
29.4 b-Adrenergic Receptor Antagonists Hollander E, Petras JN. α2-Adrenergic receptor agonists: C...
05 - 29.5 Anticholinergic Agents
29.5 Anticholinergic Agents tablets. Metoprolol is available in 50- and 100-mg tablets and 50-, 1...
06 - 29.6 Anticonvulsants
29.6 Anticonvulsants Textbook of Psychiatry. 9th ed. Vol. 2. Philadelphia: Lippincott Williams & ...
07 - 29.7 Antihistamines
29.7 Antihistamines Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of preg...
08 - 29.8 Barbiturates and Similarly Acting Drugs
29.8 Barbiturates and Similarly Acting Drugs Hydroxyzine is most commonly used as a short-term an...
09 - 29.9 Benzodiazepines and Drugs Acting on GABA
29.9 Benzodiazepines and Drugs Acting on GABA Receptors addition, the carrier can impair macropha...
10 - 29.10 Bupropion
29.10 Bupropion Conversely, oxazepam has an approximate dosage equivalence of 15 mg and is a lowp...
11 - 29.11 Buspirone
29.11 Buspirone dosage should not exceed 450 mg. The maximum of 400 mg of the sustained-release v...
12 - 29.12 Calcium Channel Blockers
29.12 Calcium Channel Blockers Myers RA, Plym MJ, Signor LJ, Lodge NJ. 1-(2-pyrimidinyl)-piperazi...
13 - 29.13 Carbamazepine and Oxcarbazepine
29.13 Carbamazepine and Oxcarbazepine old or with a history of cardiac illness) should be routine...
14 - 29.14 Cholinesterase Inhibitors and Memantine
29.14 Cholinesterase Inhibitors and Memantine concentrations early in the course of treatment bec...
15 - 29.15 Disulfiram and Acamprosate
29.15 Disulfiram and Acamprosate Droogsma E, Veeger N, van Walderveen P, Niemarkt S, van Asselt D...
16 - 29.16 Dopamine Receptor Agonists and Precurso
29.16 Dopamine Receptor Agonists and Precursors Ritvo JI, Park C. The psychiatric management of p...
17 - 29.17 Dopamine Receptor Antagonists (First Ge
29.17 Dopamine Receptor Antagonists (First-Generation Antipsychotics) schizophrenia. Br J Psychia...
18 - 29.18 Lamotrigine
29.18 Lamotrigine effects (e.g., cardiac, hypotensive, epileptogenic, sexual, and allergic) with ...
19 - 29.19 Lithium
29.19 Lithium Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK. Lamotrigine treatment of agg...
20 - 29.20 Melatonin Agonists Ramelteon and Melato
29.20 Melatonin Agonists: Ramelteon and Melatonin Einat H, Manji HK. Cellular plasticity cascades...
21 - 29.21 Mirtazapine
29.21 Mirtazapine pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug ...
22 - 29.22 Monoamine Oxidase Inhibitors
29.22 Monoamine Oxidase Inhibitors 9th edition. Vol. 2. Philadelphia: Lippincott Williams & Wilki...
23 - 29.23 Nefazodone and Trazodone
29.23 Nefazodone and Trazodone antidepressant drug treatments. Brain Res. 2008;1211:37. Baker GB,...
24 - 29.24 Opioid Receptor Agonists
29.24 Opioid Receptor Agonists randomized double-blind placebo-controlled trial. Addiction. 2005;...
25 - 29.25 Opioid Receptor Antagonists Naltrexone,
29.25 Opioid Receptor Antagonists: Naltrexone, Nalmefene, and Naloxone Strain EC, Moody DE, Stoll...
26 - 29.26 Phosphodiesterase 5 Inhibitors
29.26 Phosphodiesterase-5 Inhibitors King A, De Wit H, Riley RC, Cao D, Niaura R. Efficacy of nal...
27 - 29.27 Selective SerotoninNorepinephrine Reupt
29.27 Selective Serotonin–Norepinephrine Reuptake Inhibitors Assoc Nurses AIDS Care. 2013;24(1 Su...
28 - 29.28 Selective Serotonin Reuptake Inhibitors
29.28 Selective Serotonin Reuptake Inhibitors Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton...
29 - 29.29 SerotoninDopamine Antagonists and Simil
29.29 Serotonin–Dopamine Antagonists and Similarly Acting Drugs (Second-Generation or Atypical An...
30 - 29.30 Stimulant Drugs and Atomoxetine
29.30 Stimulant Drugs and Atomoxetine Suzuki H, Gen K, Inoue Y. Comparison of the anti-dopamine D...
31 - 29.31 Thyroid Hormones
29.31 Thyroid Hormones McElroy SL, Guerdjikova A, Kotwal R, Weige JA, Nelson EB. Atomoxetine in t...
32 - 29.32 Tricyclics and Tetracyclics
29.32 Tricyclics and Tetracyclics risk for postpartum depressive symptoms. Psychoneuroendocrinolo...
33 - 29.33 Valproate
29.33 Valproate Psychiatry. 1990;47:1093. Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber ...
34 - 29.34 Nutritional Supplements and Medical Foo
29.34 Nutritional Supplements and Medical Foods 29.34 Nutritional Supplements and Medical Foods T...
35 - 29.35 Weight Loss Drugs
29.35 Weight Loss Drugs REFERENCES Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatmen...